These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34778995)

  • 1. Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.
    Kastritis E; Terpos E; Evangelakou Z; Theodorakakou F; Fotiou D; Manola MS; Gianniou DD; Bagratuni T; Kanellias N; Migkou M; Gavriatopoulou M; Trougakos IP; Dimopoulos MA
    Am J Hematol; 2022 Jan; 97(1):E27-E31. PubMed ID: 34778995
    [No Abstract]   [Full Text] [Related]  

  • 2. Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.
    Schiller Salton N; Szwarcwort M; Tzoran I; Horowitz NA; Zuckerman T; Horesh N; Shachor-Meyouhas Y; Hussein K; Lavi N
    Am J Hematol; 2021 Dec; 96(12):E475-E478. PubMed ID: 34622495
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
    Miyakawa K; Jeremiah SS; Kato H; Yamaoka Y; Go H; Yajima S; Shimada T; Mihara T; Goto A; Yamanaka T; Ryo A
    J Mol Cell Biol; 2022 Jan; 13(12):918-920. PubMed ID: 34450642
    [No Abstract]   [Full Text] [Related]  

  • 4. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
    Rosati M; Terpos E; Agarwal M; Karalis V; Bear J; Burns R; Hu X; Papademetriou D; Ntanasis-Stathopoulos I; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK
    Am J Hematol; 2022 Jan; 97(1):E3-E7. PubMed ID: 34674297
    [No Abstract]   [Full Text] [Related]  

  • 6. Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study.
    Paschou SA; Karalis V; Psaltopoulou T; Vasileiou V; Charitaki I; Bagratuni T; Ktena V; Papandroulaki F; Gumeni S; Kassi GN; Trougakos IP; Terpos E; Dimopoulos MA
    Front Endocrinol (Lausanne); 2022; 13():840668. PubMed ID: 35273575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
    Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
    Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.
    Attolico I; Tarantini F; Carluccio P; Schifone CP; Delia M; Gagliardi VP; Perrone T; Gaudio F; Longo C; Giordano A; Sgherza N; Curci P; Rizzi R; Ricco A; Russo Rossi A; Albano F; Larocca AMV; Vimercati L; Tafuri S; Musto P
    Br J Haematol; 2022 Feb; 196(4):928-931. PubMed ID: 34664267
    [No Abstract]   [Full Text] [Related]  

  • 9. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
    Messali S; Bertelli A; Campisi G; Zani A; Ciccozzi M; Caruso A; Caccuri F
    J Med Virol; 2021 Dec; 93(12):6468-6470. PubMed ID: 34329486
    [No Abstract]   [Full Text] [Related]  

  • 10. The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Marchesi F; Pimpinelli F; Sperandio E; Papa E; Falcucci P; Pontone M; di Martino S; de Latouliere L; Orlandi G; Morrone A; Ciliberto G; Mengarelli A;
    Br J Haematol; 2022 Jan; 196(2):362-367. PubMed ID: 34490627
    [No Abstract]   [Full Text] [Related]  

  • 11. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 12. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
    Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
    Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
    Front Immunol; 2021; 12():743422. PubMed ID: 34659239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
    Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahé B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Jullien M; Vantyghem S; Moreau P; Le Gouill S; Béné MC; Chevallier P
    Br J Haematol; 2022 Mar; 196(5):e38-e40. PubMed ID: 34671982
    [No Abstract]   [Full Text] [Related]  

  • 16. Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination.
    Iketani S; Liu L; Nair MS; Chandrashekar A; Mohri H; Wang M; Barouch DH; Huang Y; Ho DD
    Emerg Microbes Infect; 2021 Dec; 10(1):2220-2222. PubMed ID: 34779713
    [No Abstract]   [Full Text] [Related]  

  • 17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
    Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
    Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.